Related Experiment Videos
Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants
Insights
A live attenuated experimental vaccine for Respiratory Syncytial Virus (RS virus) ts-1 was tested in infants. The study found that 8 out of 25 infants showed successful infection with the vaccine.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Respiratory Syncytial Virus (RS virus) is a common cause of respiratory illness in infants.
- Live attenuated vaccines are a potential strategy for preventing RS virus infections.
Purpose of the Study:
- To evaluate the safety and immunogenicity of an experimental live attenuated RS virus ts-1 vaccine.
- To assess the infection rate of the RS virus ts-1 vaccine in infants.
Main Methods:
- A controlled, double-blind study was conducted with 25 infants aged 11-19 months.
- The vaccine was administered intranasally at a dose of 100 TCID50.
- Infection was determined by virus shedding or antibody response.
Main Results:
- 8 out of 25 infants (32%) showed evidence of successful infection with the RS virus ts-1 vaccine.
- The study design controlled for observer bias and assessed intercurrent illness.
Conclusions:
- The live attenuated RS virus ts-1 vaccine demonstrated an infection rate of 32% in infants at the tested dose.
- Further research may be warranted to optimize vaccine efficacy and safety.
Abstract:
Respiratory syncytial virus ts-1 is a live attenuated experimental vaccine which was administered intranasally to 25 infants 11 to 19 months of age. Clinical evaluation was carried out following a controlled, double-blind protocol which eliminated observer bias, assessed intercurrent illness, and was designed to detect virus transmission. At the low dose of virus of virus used (100 TCID50) 8 of the 25 recipients were successfully infected with RS virus ts-1 as determined by virus shedding or antibody response.